ID   MED1_HUMAN              Reviewed;        1581 AA.
AC   Q15648; A2RRQ6; O43810; O75447; Q6P9H7; Q6PK58; Q9HD39;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 4.
DT   15-MAR-2017, entry version 172.
DE   RecName: Full=Mediator of RNA polymerase II transcription subunit 1;
DE   AltName: Full=Activator-recruited cofactor 205 kDa component;
DE            Short=ARC205;
DE   AltName: Full=Mediator complex subunit 1;
DE   AltName: Full=Peroxisome proliferator-activated receptor-binding protein;
DE            Short=PBP;
DE            Short=PPAR-binding protein;
DE   AltName: Full=Thyroid hormone receptor-associated protein complex 220 kDa component;
DE            Short=Trap220;
DE   AltName: Full=Thyroid receptor-interacting protein 2;
DE            Short=TR-interacting protein 2;
DE            Short=TRIP-2;
DE   AltName: Full=Vitamin D receptor-interacting protein complex component DRIP205;
DE   AltName: Full=p53 regulatory protein RB18A;
GN   Name=MED1;
GN   Synonyms=ARC205, CRSP1, CRSP200, DRIP205, DRIP230, PBP, PPARBP,
GN   PPARGBP, RB18A, TRAP220, TRIP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DNA-BINDING, INTERACTION WITH
RP   TP53, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=9444950; DOI=10.1038/sj.onc.1201492;
RA   Drane P., Barel M., Balbo M., Frade R.;
RT   "Identification of RB18A, a 205 kDa new p53 regulatory protein which
RT   shares antigenic and functional properties with p53.";
RL   Oncogene 15:3013-3024(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 157-168;
RP   943-952 AND 1432-1442, FUNCTION, INTERACTION WITH ESR1; PPARA; PPARG;
RP   RARA; RXRA; THRA AND VDR, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=9653119; DOI=10.1073/pnas.95.14.7939;
RA   Yuan C.-X., Ito M., Fondell J.D., Fu Z.-Y., Roeder R.G.;
RT   "The TRAP220 component of a thyroid hormone receptor-associated
RT   protein (TRAP) coactivator complex interacts directly with nuclear
RT   receptors in a ligand-dependent fashion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7939-7944(1998).
RN   [3]
RP   ERRATUM.
RA   Yuan C.-X., Ito M., Fondell J.D., Fu Z.-Y., Roeder R.G.;
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14584-14584(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-13 AND 1452-1464, AND IDENTIFICATION IN THE ARC
RP   COMPLEX.
RX   PubMed=10235267; DOI=10.1038/19789;
RA   Naeaer A.M., Beaurang P.A., Zhou S., Abraham S., Solomon W.B.,
RA   Tjian R.;
RT   "Composite co-activator ARC mediates chromatin-directed
RT   transcriptional activation.";
RL   Nature 398:828-832(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-1581 (ISOFORM 1), INTERACTION WITH
RP   VDR, AND MUTAGENESIS OF 607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=10733574; DOI=10.1128/MCB.20.8.2718-2726.2000;
RA   Rachez C., Gamble M., Chang C.-P.B., Atkins G.B., Lazar M.A.,
RA   Freedman L.P.;
RT   "The DRIP complex and SRC-1/p160 coactivators share similar nuclear
RT   receptor binding determinants but constitute functionally distinct
RT   complexes.";
RL   Mol. Cell. Biol. 20:2718-2726(2000).
RN   [8]
RP   PROTEIN SEQUENCE OF 307-315 AND 584-597, IDENTIFICATION IN THE DRIP
RP   COMPLEX, AND INTERACTION WITH VDR.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10235266; DOI=10.1038/19783;
RA   Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M.,
RA   Naeaer A.M., Erdjument-Bromage H., Tempst P., Freedman L.P.;
RT   "Ligand-dependent transcription activation by nuclear receptors
RT   requires the DRIP complex.";
RL   Nature 398:824-828(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 622-711.
RX   PubMed=7776974; DOI=10.1210/mend.9.2.7776974;
RA   Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D.;
RT   "Two classes of proteins dependent on either the presence or absence
RT   of thyroid hormone for interaction with the thyroid hormone
RT   receptor.";
RL   Mol. Endocrinol. 9:243-254(1995).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SMCC
RP   COMPLEX.
RX   PubMed=10024883; DOI=10.1016/S1097-2765(00)80178-1;
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X.,
RA   Martinez E., Qin J., Roeder R.G.;
RT   "A novel human SRB/MED-containing cofactor complex, SMCC, involved in
RT   transcription regulation.";
RL   Mol. Cell 3:97-108(1999).
RN   [11]
RP   ERRATUM.
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X.,
RA   Martinez E., Qin J., Roeder R.G.;
RL   Mol. Cell 3:541-541(1999).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MED24; THRA; THRB AND VDR.
RX   PubMed=10406464; DOI=10.1210/mend.13.7.0295;
RA   Zhang J., Fondell J.D.;
RT   "Identification of mouse TRAP100: a transcriptional coregulatory
RT   factor for thyroid hormone and vitamin D receptors.";
RL   Mol. Endocrinol. 13:1130-1140(1999).
RN   [13]
RP   INTERACTION WITH RORA.
RX   PubMed=10478845; DOI=10.1210/mend.13.9.0343;
RA   Atkins G.B., Hu X., Guenther M.G., Rachez C., Freedman L.P.,
RA   Lazar M.A.;
RT   "Coactivators for the orphan nuclear receptor RORalpha.";
RL   Mol. Endocrinol. 13:1550-1557(1999).
RN   [14]
RP   INTERACTION WITH ESR1; ESR2 AND VDR, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=10770935; DOI=10.1074/jbc.M002013200;
RA   Burakov D., Wong C.-W., Rachez C., Cheskis B.J., Freedman L.P.;
RT   "Functional interactions between the estrogen receptor and DRIP205, a
RT   subunit of the heteromeric DRIP coactivator complex.";
RL   J. Biol. Chem. 275:20928-20934(2000).
RN   [15]
RP   INTERACTION WITH ESR1 AND ESR2, AND MUTAGENESIS OF 599-SER--GLY-612;
RP   LEU-604; LEU-607; LEU-645 AND LEU-648.
RX   PubMed=11303023; DOI=10.1074/jbc.M011651200;
RA   Waernmark A., Almloef T., Leers J., Gustafsson J.-A., Treuter E.;
RT   "Differential recruitment of the mammalian mediator subunit TRAP220 by
RT   estrogen receptors ERalpha and ERbeta.";
RL   J. Biol. Chem. 276:23397-23404(2001).
RN   [16]
RP   FUNCTION, INTERACTION WITH AR, AND ASSOCIATION WITH PROMOTER REGIONS.
RX   PubMed=12218053; DOI=10.1074/jbc.M206061200;
RA   Wang Q., Sharma D., Ren Y., Fondell J.D.;
RT   "A coregulatory role for the TRAP-mediator complex in androgen
RT   receptor-mediated gene expression.";
RL   J. Biol. Chem. 277:42852-42858(2002).
RN   [17]
RP   FUNCTION, AND INTERACTION OF THE MEDIATOR COMPLEX WITH PPARG.
RX   PubMed=12037571; DOI=10.1038/417563a;
RA   Ge K., Guermah M., Yuan C.-X., Ito M., Wallberg A.E., Spiegelman B.M.,
RA   Roeder R.G.;
RT   "Transcription coactivator TRAP220 is required for PPAR gamma 2-
RT   stimulated adipogenesis.";
RL   Nature 417:563-567(2002).
RN   [18]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX, AND INTERACTION OF THE MEDIATOR COMPLEX WITH ESR1
RP   AND ESR2.
RX   PubMed=11867769; DOI=10.1073/pnas.261715899;
RA   Kang Y.K., Guermah M., Yuan C.-X., Roeder R.G.;
RT   "The TRAP/Mediator coactivator complex interacts directly with
RT   estrogen receptors alpha and beta through the TRAP220 subunit and
RT   directly enhances estrogen receptor function in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2642-2647(2002).
RN   [19]
RP   ASSOCIATION WITH PROMOTER REGIONS.
RX   PubMed=12034878; DOI=10.1073/pnas.122004799;
RA   Sharma D., Fondell J.D.;
RT   "Ordered recruitment of histone acetyltransferases and the
RT   TRAP/Mediator complex to thyroid hormone-responsive promoters in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7934-7939(2002).
RN   [20]
RP   FUNCTION, INTERACTION WITH ESR1; PPARG; RARA; RXRA AND THRB, AND
RP   MUTAGENESIS OF 600-GLN--SER-612; 607-LEU-LEU-608; 639-THR--PRO-653 AND
RP   648-LEU-LEU-649.
RX   PubMed=12556447; DOI=10.1074/jbc.M212950200;
RA   Coulthard V.H., Matsuda S., Heery D.M.;
RT   "An extended LXXLL motif sequence determines the nuclear receptor
RT   binding specificity of TRAP220.";
RL   J. Biol. Chem. 278:10942-10951(2003).
RN   [21]
RP   FUNCTION, INTERACTION WITH PPARGC1A, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=14636573; DOI=10.1016/S1097-2765(03)00391-5;
RA   Wallberg A.E., Yamamura S., Malik S., Spiegelman B.M., Roeder R.G.;
RT   "Coordination of p300-mediated chromatin remodeling and TRAP/mediator
RT   function through coactivator PGC-1alpha.";
RL   Mol. Cell 12:1137-1149(2003).
RN   [22]
RP   FUNCTION, INTERACTION WITH ESR1, AND SUBCELLULAR LOCATION.
RX   PubMed=15471764; DOI=10.1074/jbc.M409778200;
RA   Wu Q., Burghardt R., Safe S.;
RT   "Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen
RT   receptor alpha (ERalpha) involves multiple domains of both proteins.";
RL   J. Biol. Chem. 279:53602-53612(2004).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX.
RX   PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006;
RA   Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B.,
RA   Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P.,
RA   Conaway J.W., Conaway R.C.;
RT   "A set of consensus mammalian mediator subunits identified by
RT   multidimensional protein identification technology.";
RL   Mol. Cell 14:685-691(2004).
RN   [24]
RP   FUNCTION, INTERACTION OF THE MEDIATOR COMPLEX WITH THRA, AND
RP   MUTAGENESIS OF 607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=15340084; DOI=10.1128/MCB.24.18.8244-8254.2004;
RA   Malik S., Guermah M., Yuan C.-X., Wu W., Yamamura S., Roeder R.G.;
RT   "Structural and functional organization of TRAP220, the TRAP/mediator
RT   subunit that is targeted by nuclear receptors.";
RL   Mol. Cell. Biol. 24:8244-8254(2004).
RN   [25]
RP   FUNCTION, ASSOCIATION WITH PROMOTER REGIONS, INTERACTION WITH CCNC;
RP   MED6; MED10; MED11; MED12; MED13; MED14; MED15; MED16; MED17; MED18;
RP   MED19; MED20; MED21; MED23; MED24; MED25; MED26; MED28; MED29 AND
RP   MED30, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX, AND ASSOCIATION OF THE MEDIATOR COMPLEX WITH RNA
RP   POLYMERASE II.
RX   PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015;
RA   Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T.,
RA   Roeder R.G.;
RT   "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation
RT   enriched in RNA polymerase II and is required for ER-mediated
RT   transcription.";
RL   Mol. Cell 19:89-100(2005).
RN   [26]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-1032 AND THR-1457, AND
RP   MUTAGENESIS OF THR-1032 AND THR-1457.
RX   PubMed=16314496; DOI=10.1128/MCB.25.24.10695-10710.2005;
RA   Pandey P.K., Udayakumar T.S., Lin X., Sharma D., Shapiro P.S.,
RA   Fondell J.D.;
RT   "Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by
RT   mitogen-activated protein kinase-dependent phosphorylation.";
RL   Mol. Cell. Biol. 25:10695-10710(2005).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [28]
RP   FUNCTION, INTERACTION WITH GABPA, ASSOCIATION WITH PROMOTER REGIONS,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16574658; DOI=10.1074/jbc.M600163200;
RA   Udayakumar T.S., Belakavadi M., Choi K.-H., Pandey P.K., Fondell J.D.;
RT   "Regulation of Aurora-A kinase gene expression via GABP recruitment of
RT   TRAP220/MED1.";
RL   J. Biol. Chem. 281:14691-14699(2006).
RN   [29]
RP   INTERACTION WITH CDK8.
RX   PubMed=17000779; DOI=10.1128/MCB.00443-06;
RA   Zhou H., Kim S., Ishii S., Boyer T.G.;
RT   "Mediator modulates Gli3-dependent Sonic hedgehog signaling.";
RL   Mol. Cell. Biol. 26:8667-8682(2006).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-795; THR-805 AND
RP   THR-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-805; THR-1057; SER-1207
RP   AND THR-1215, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-1051; THR-1057;
RP   SER-1207; THR-1215; SER-1463; SER-1479; SER-1481 AND SER-1482, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-805 AND THR-1215, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   INTERACTION WITH RXRA.
RX   PubMed=19786558; DOI=10.1124/mol.109.057000;
RA   Cho Y., Noshiro M., Choi M., Morita K., Kawamoto T., Fujimoto K.,
RA   Kato Y., Makishima M.;
RT   "The basic helix-loop-helix proteins differentiated embryo chondrocyte
RT   (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.";
RL   Mol. Pharmacol. 76:1360-1369(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-1051; THR-1057;
RP   SER-1463; SER-1479; SER-1481 AND SER-1482, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1177 AND LYS-1529, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-805; THR-1057;
RP   SER-1207; THR-1215; SER-1347; SER-1403 AND SER-1433, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1051; SER-1156;
RP   SER-1207; THR-1215; SER-1223 AND SER-1479, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588; SER-664; THR-805;
RP   THR-1051; THR-1057; SER-1156; SER-1207; THR-1215; SER-1223; SER-1302;
RP   SER-1433; THR-1440; SER-1463; SER-1479; SER-1481 AND SER-1482, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   FUNCTION, AND INTERACTION WITH GATA1 AND CCAR1.
RX   PubMed=24245781; DOI=10.1111/gtc.12104;
RA   Mizuta S., Minami T., Fujita H., Kaminaga C., Matsui K., Ishino R.,
RA   Fujita A., Oda K., Kawai A., Hasegawa N., Urahama N., Roeder R.G.,
RA   Ito M.;
RT   "CCAR1/CoCoA pair-mediated recruitment of the Mediator defines a novel
RT   pathway for GATA1 function.";
RL   Genes Cells 19:28-51(2014).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the Mediator complex, a coactivator
CC       involved in the regulated transcription of nearly all RNA
CC       polymerase II-dependent genes. Mediator functions as a bridge to
CC       convey information from gene-specific regulatory proteins to the
CC       basal RNA polymerase II transcription machinery. Mediator is
CC       recruited to promoters by direct interactions with regulatory
CC       proteins and serves as a scaffold for the assembly of a functional
CC       preinitiation complex with RNA polymerase II and the general
CC       transcription factors (PubMed:10406464, PubMed:11867769,
CC       PubMed:12037571, PubMed:12218053, PubMed:12556447,
CC       PubMed:14636573, PubMed:15340084, PubMed:15471764,
CC       PubMed:15989967, PubMed:16574658, PubMed:9653119). Acts as a
CC       coactivator for GATA1-mediated transcriptional activation during
CC       erythroid differentiation of K562 erythroleukemia cells
CC       (PubMed:24245781). {ECO:0000269|PubMed:10406464,
CC       ECO:0000269|PubMed:11867769, ECO:0000269|PubMed:12037571,
CC       ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:12556447,
CC       ECO:0000269|PubMed:14636573, ECO:0000269|PubMed:15340084,
CC       ECO:0000269|PubMed:15471764, ECO:0000269|PubMed:15989967,
CC       ECO:0000269|PubMed:16574658, ECO:0000269|PubMed:24245781,
CC       ECO:0000269|PubMed:9653119}.
CC   -!- SUBUNIT: Component of the Mediator complex, which is composed of
CC       MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13,
CC       MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21,
CC       MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31,
CC       CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8
CC       subunits form a distinct module termed the CDK8 module. Mediator
CC       containing the CDK8 module is less active than Mediator lacking
CC       this module in supporting transcriptional activation. Individual
CC       preparations of the Mediator complex lacking one or more distinct
CC       subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and
CC       TRAP. This subunit specifically interacts with a number of nuclear
CC       receptors in a ligand-dependent fashion including AR, ESR1, ESR2,
CC       PPARA, PPARG, RORA, RXRA, RXRG, THRA, THRB and VDR. Interacts with
CC       CTNNB1, GABPA, GLI3, PPARGC1A and TP53. Interacts with YWHAH.
CC       Interacts with CLOCK; this interaction requires the presence of
CC       THRAP3 (By similarity). Interacts with GATA1 and CCAR1. Interacts
CC       with NR4A3 (By similarity). {ECO:0000250|UniProtKB:Q925J9,
CC       ECO:0000269|PubMed:10024883, ECO:0000269|PubMed:10235266,
CC       ECO:0000269|PubMed:10235267, ECO:0000269|PubMed:10406464,
CC       ECO:0000269|PubMed:10478845, ECO:0000269|PubMed:10733574,
CC       ECO:0000269|PubMed:10770935, ECO:0000269|PubMed:11303023,
CC       ECO:0000269|PubMed:11867769, ECO:0000269|PubMed:12037571,
CC       ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:12556447,
CC       ECO:0000269|PubMed:14636573, ECO:0000269|PubMed:15175163,
CC       ECO:0000269|PubMed:15340084, ECO:0000269|PubMed:15471764,
CC       ECO:0000269|PubMed:15989967, ECO:0000269|PubMed:16574658,
CC       ECO:0000269|PubMed:17000779, ECO:0000269|PubMed:19786558,
CC       ECO:0000269|PubMed:24245781, ECO:0000269|PubMed:9444950,
CC       ECO:0000269|PubMed:9653119}.
CC   -!- INTERACTION:
CC       O43513:MED7; NbExp=4; IntAct=EBI-394459, EBI-394632;
CC       P10276:RARA; NbExp=3; IntAct=EBI-394459, EBI-413374;
CC       P10827:THRA; NbExp=5; IntAct=EBI-394459, EBI-286285;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15471764,
CC       ECO:0000269|PubMed:16314496, ECO:0000269|PubMed:16574658}. Note=A
CC       subset of the protein may enter the nucleolus subsequent to
CC       phosphorylation by MAPK1 or MAPK3.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15648-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15648-3; Sequence=VSP_027906, VSP_027907;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:9444950, ECO:0000269|PubMed:9653119}.
CC   -!- PTM: Phosphorylated by MAPK1 or MAPK3 during G2/M phase which may
CC       enhance protein stability and promote entry into the nucleolus.
CC       {ECO:0000269|PubMed:16314496}.
CC   -!- SIMILARITY: Belongs to the Mediator complex subunit 1 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39854.1; Type=Frameshift; Positions=543, 545; Evidence={ECO:0000305};
CC       Sequence=AAH06517.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=CAA73867.1; Type=Frameshift; Positions=4; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13467; CAA73867.1; ALT_FRAME; mRNA.
DR   EMBL; AF055994; AAC39854.1; ALT_FRAME; mRNA.
DR   EMBL; CH471152; EAW60575.1; -; Genomic_DNA.
DR   EMBL; BC006517; AAH06517.1; ALT_TERM; mRNA.
DR   EMBL; BC060758; AAH60758.1; -; mRNA.
DR   EMBL; BC131783; AAI31784.1; -; mRNA.
DR   EMBL; AF283812; AAF98352.1; -; mRNA.
DR   EMBL; L40366; AAC41736.1; -; mRNA.
DR   CCDS; CCDS11336.1; -. [Q15648-1]
DR   RefSeq; NP_004765.2; NM_004774.3. [Q15648-1]
DR   UniGene; Hs.643754; -.
DR   PDB; 1RJK; X-ray; 1.99 A; C=640-652.
DR   PDB; 1RK3; X-ray; 2.20 A; C=640-652.
DR   PDB; 1RKG; X-ray; 1.90 A; C=640-652.
DR   PDB; 1RKH; X-ray; 2.28 A; C=640-652.
DR   PDB; 2O4J; X-ray; 1.74 A; C=640-652.
DR   PDB; 2O4R; X-ray; 1.98 A; C=640-652.
DR   PDB; 2ZFX; X-ray; 1.99 A; C=640-652.
DR   PDB; 3A2H; X-ray; 2.50 A; B=640-652.
DR   PDB; 3AUN; X-ray; 1.81 A; B=640-652.
DR   PDB; 3VJS; X-ray; 1.93 A; C=640-652.
DR   PDB; 3VJT; X-ray; 2.00 A; C=640-652.
DR   PDB; 3VRT; X-ray; 2.40 A; C=640-652.
DR   PDB; 3VRU; X-ray; 2.00 A; C=640-652.
DR   PDB; 3VRV; X-ray; 1.90 A; C=640-652.
DR   PDB; 3VRW; X-ray; 2.40 A; C=640-652.
DR   PDB; 3W0G; X-ray; 1.94 A; C=640-652.
DR   PDB; 3W0H; X-ray; 1.80 A; C=640-652.
DR   PDB; 3W0I; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W0J; X-ray; 1.84 A; C=640-652.
DR   PDB; 3W5P; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W5Q; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W5R; X-ray; 2.20 A; C=640-652.
DR   PDB; 3W5T; X-ray; 2.29 A; C=640-652.
DR   PDB; 3WT5; X-ray; 1.90 A; C=640-652.
DR   PDB; 3WT6; X-ray; 2.00 A; C=640-652.
DR   PDB; 3WT7; X-ray; 2.40 A; C=640-652.
DR   PDB; 3WTQ; X-ray; 2.10 A; C=640-652.
DR   PDB; 4YNK; X-ray; 2.30 A; C=640-652.
DR   PDB; 5AWJ; X-ray; 2.20 A; C=640-652.
DR   PDB; 5AWK; X-ray; 2.90 A; C=640-652.
DR   PDB; 5B41; X-ray; 1.89 A; C=640-652.
DR   PDB; 5B5B; X-ray; 2.00 A; C/F=640-652.
DR   PDB; 5GIC; X-ray; 2.35 A; C=641-650.
DR   PDB; 5GID; X-ray; 2.15 A; C=641-649.
DR   PDB; 5GIE; X-ray; 2.39 A; C/E=641-650.
DR   PDBsum; 1RJK; -.
DR   PDBsum; 1RK3; -.
DR   PDBsum; 1RKG; -.
DR   PDBsum; 1RKH; -.
DR   PDBsum; 2O4J; -.
DR   PDBsum; 2O4R; -.
DR   PDBsum; 2ZFX; -.
DR   PDBsum; 3A2H; -.
DR   PDBsum; 3AUN; -.
DR   PDBsum; 3VJS; -.
DR   PDBsum; 3VJT; -.
DR   PDBsum; 3VRT; -.
DR   PDBsum; 3VRU; -.
DR   PDBsum; 3VRV; -.
DR   PDBsum; 3VRW; -.
DR   PDBsum; 3W0G; -.
DR   PDBsum; 3W0H; -.
DR   PDBsum; 3W0I; -.
DR   PDBsum; 3W0J; -.
DR   PDBsum; 3W5P; -.
DR   PDBsum; 3W5Q; -.
DR   PDBsum; 3W5R; -.
DR   PDBsum; 3W5T; -.
DR   PDBsum; 3WT5; -.
DR   PDBsum; 3WT6; -.
DR   PDBsum; 3WT7; -.
DR   PDBsum; 3WTQ; -.
DR   PDBsum; 4YNK; -.
DR   PDBsum; 5AWJ; -.
DR   PDBsum; 5AWK; -.
DR   PDBsum; 5B41; -.
DR   PDBsum; 5B5B; -.
DR   PDBsum; 5GIC; -.
DR   PDBsum; 5GID; -.
DR   PDBsum; 5GIE; -.
DR   ProteinModelPortal; Q15648; -.
DR   SMR; Q15648; -.
DR   BioGrid; 111465; 101.
DR   DIP; DIP-24212N; -.
DR   IntAct; Q15648; 40.
DR   MINT; MINT-1345780; -.
DR   STRING; 9606.ENSP00000300651; -.
DR   iPTMnet; Q15648; -.
DR   PhosphoSitePlus; Q15648; -.
DR   BioMuta; MED1; -.
DR   DMDM; 158518535; -.
DR   EPD; Q15648; -.
DR   MaxQB; Q15648; -.
DR   PaxDb; Q15648; -.
DR   PeptideAtlas; Q15648; -.
DR   PRIDE; Q15648; -.
DR   DNASU; 5469; -.
DR   Ensembl; ENST00000300651; ENSP00000300651; ENSG00000125686. [Q15648-1]
DR   Ensembl; ENST00000394287; ENSP00000377828; ENSG00000125686. [Q15648-3]
DR   GeneID; 5469; -.
DR   KEGG; hsa:5469; -.
DR   UCSC; uc002hru.3; human. [Q15648-1]
DR   CTD; 5469; -.
DR   DisGeNET; 5469; -.
DR   GeneCards; MED1; -.
DR   HGNC; HGNC:9234; MED1.
DR   HPA; CAB017696; -.
DR   HPA; HPA052818; -.
DR   MIM; 604311; gene.
DR   neXtProt; NX_Q15648; -.
DR   OpenTargets; ENSG00000125686; -.
DR   PharmGKB; PA33556; -.
DR   eggNOG; ENOG410IEFR; Eukaryota.
DR   eggNOG; ENOG410XR2E; LUCA.
DR   GeneTree; ENSGT00660000095569; -.
DR   HOVERGEN; HBG101127; -.
DR   InParanoid; Q15648; -.
DR   KO; K15144; -.
DR   OMA; HGEDFSK; -.
DR   OrthoDB; EOG091G035E; -.
DR   PhylomeDB; Q15648; -.
DR   TreeFam; TF324954; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-212436; Generic Transcription Pathway.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SignaLink; Q15648; -.
DR   SIGNOR; Q15648; -.
DR   ChiTaRS; MED1; human.
DR   EvolutionaryTrace; Q15648; -.
DR   GeneWiki; MED1; -.
DR   GenomeRNAi; 5469; -.
DR   PRO; PR:Q15648; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000125686; -.
DR   CleanEx; HS_MED1; -.
DR   ExpressionAtlas; Q15648; baseline and differential.
DR   Genevisible; Q15648; HS.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0016592; C:mediator complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IEA:Ensembl.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IMP:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:UniProtKB.
DR   GO; GO:0050693; F:LBD domain binding; IPI:UniProtKB.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IDA:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0036033; F:mediator complex binding; IDA:UniProtKB.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0042975; F:peroxisome proliferator activated receptor binding; IPI:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IDA:UniProtKB.
DR   GO; GO:0042974; F:retinoic acid receptor binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001104; F:RNA polymerase II transcription cofactor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0030375; F:thyroid hormone receptor coactivator activity; IMP:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription cofactor activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0042809; F:vitamin D receptor binding; IPI:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IMP:UniProtKB.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0035050; P:embryonic heart tube development; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0048822; P:enucleate erythrocyte development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048821; P:erythrocyte development; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IDA:MGI.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070318; P:positive regulation of G0 to G1 transition; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:2000347; P:positive regulation of hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0060335; P:positive regulation of interferon-gamma-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0033601; P:positive regulation of mammary gland epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:2000273; P:positive regulation of receptor activity; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB.
DR   GO; GO:2001141; P:regulation of RNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006356; P:regulation of transcription from RNA polymerase I promoter; IDA:UniProtKB.
DR   GO; GO:0070562; P:regulation of vitamin D receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0003406; P:retinal pigment epithelium development; IEA:Ensembl.
DR   GO; GO:0006590; P:thyroid hormone generation; IEA:Ensembl.
DR   GO; GO:0002154; P:thyroid hormone mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; IEA:Ensembl.
DR   InterPro; IPR019680; Mediator_Med1.
DR   Pfam; PF10744; Med1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; DNA-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation.
FT   CHAIN         1   1581       Mediator of RNA polymerase II
FT                                transcription subunit 1.
FT                                /FTId=PRO_0000058552.
FT   REGION        1    670       Interaction with the Mediator complex and
FT                                THRA.
FT   REGION       16    590       Interaction with ESR1.
FT   REGION      108    212       Interaction with the Mediator complex.
FT   REGION      215    390       Interaction with the Mediator complex.
FT   REGION      405    644       Interaction with THRA.
FT   REGION      542    789       Interaction with VDR.
FT   REGION      622    701       Interaction with PPARGC1A and THRA.
FT                                {ECO:0000269|PubMed:14636573}.
FT   REGION      656   1066       Interaction with ESR1.
FT   REGION      681    715       Interaction with GATA1.
FT                                {ECO:0000269|PubMed:24245781}.
FT   REGION     1249   1421       Interaction with TP53.
FT                                {ECO:0000269|PubMed:9444950}.
FT   MOTIF       604    608       LXXLL motif 1.
FT   MOTIF       645    649       LXXLL motif 2.
FT   COMPBIAS   1078   1482       Ser-rich.
FT   COMPBIAS   1496   1529       Lys-rich.
FT   MOD_RES     588    588       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     795    795       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   MOD_RES     805    805       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     953    953       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q925J9}.
FT   MOD_RES    1032   1032       Phosphothreonine; by MAPK1 or MAPK3.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MOD_RES    1051   1051       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1057   1057       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1156   1156       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1177   1177       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1207   1207       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1215   1215       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1223   1223       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1302   1302       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1347   1347       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1403   1403       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1433   1433       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1440   1440       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1457   1457       Phosphothreonine; by MAPK1 or MAPK3.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MOD_RES    1463   1463       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1465   1465       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q925J9}.
FT   MOD_RES    1479   1479       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1481   1481       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1482   1482       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1529   1529       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ     548    556       YGMTTGNNP -> SKNPELGSG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_027906.
FT   VAR_SEQ     557   1581       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_027907.
FT   VARIANT     753    753       P -> T (in dbSNP:rs1139825).
FT                                /FTId=VAR_053955.
FT   VARIANT    1240   1240       S -> G (in dbSNP:rs35668211).
FT                                /FTId=VAR_034938.
FT   MUTAGEN     599    612       SQNPILTSLLQITG->EKHKILHRLLQDSS: Enhances
FT                                interaction with ESR1.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     600    612       QNPILTSLLQITG->RHKILHRLLQEGS: Enhances
FT                                interaction with ESR1.
FT                                {ECO:0000269|PubMed:12556447}.
FT   MUTAGEN     604    604       L->A: Impairs interaction with ESR2; when
FT                                associated with A-607; A-645 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     607    608       LL->AA: Impairs interaction with ESR1,
FT                                PPARG, RXRA and THRB. Impairs interaction
FT                                with THRA; when associated with 648-A-A-
FT                                649. {ECO:0000269|PubMed:10733574,
FT                                ECO:0000269|PubMed:10770935,
FT                                ECO:0000269|PubMed:12556447,
FT                                ECO:0000269|PubMed:14636573,
FT                                ECO:0000269|PubMed:15340084,
FT                                ECO:0000269|PubMed:9653119}.
FT   MUTAGEN     607    607       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-645 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     639    653       TKNHPMLMNLLKDNP->VSRHKILHRLLQEGS:
FT                                Enhances interaction with ESR1.
FT                                {ECO:0000269|PubMed:12556447}.
FT   MUTAGEN     645    645       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-607 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     648    649       LL->AA: Impairs interaction with ESR1,
FT                                PPARG, THRB and VDR. Impairs interaction
FT                                with THRA; when associated with 607-A-A-
FT                                608. {ECO:0000269|PubMed:10733574,
FT                                ECO:0000269|PubMed:10770935,
FT                                ECO:0000269|PubMed:12556447,
FT                                ECO:0000269|PubMed:14636573,
FT                                ECO:0000269|PubMed:15340084,
FT                                ECO:0000269|PubMed:9653119}.
FT   MUTAGEN     648    648       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-607 and A-645.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN    1032   1032       T->A: Enhances protein stability; when
FT                                associated with A-1457.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MUTAGEN    1457   1457       T->A: Enhances protein stability; when
FT                                associated with A-1032.
FT                                {ECO:0000269|PubMed:16314496}.
FT   CONFLICT     86     86       R -> G (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    147    147       F -> S (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    471    472       DS -> GL (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    563    563       P -> S (in Ref. 1; CAA73867 and 7;
FT                                AAF98352). {ECO:0000305}.
FT   CONFLICT    573    573       T -> A (in Ref. 1; CAA73867 and 7;
FT                                AAF98352). {ECO:0000305}.
FT   CONFLICT    651    651       D -> N (in Ref. 5; AAH06517).
FT                                {ECO:0000305}.
FT   CONFLICT    673    673       S -> F (in Ref. 9; AAC41736).
FT                                {ECO:0000305}.
FT   CONFLICT    702    708       Missing (in Ref. 9; AAC41736).
FT                                {ECO:0000305}.
FT   CONFLICT    721    721       N -> K (in Ref. 2; AAC39854).
FT                                {ECO:0000305}.
FT   CONFLICT    728    728       M -> R (in Ref. 7; AAF98352).
FT                                {ECO:0000305}.
FT   CONFLICT    756    761       VPHPQP -> FYLTPQ (in Ref. 5; AAH06517).
FT                                {ECO:0000305}.
FT   CONFLICT   1388   1388       G -> S (in Ref. 2; AAC39854).
FT                                {ECO:0000305}.
FT   HELIX       643    649       {ECO:0000244|PDB:2O4J}.
SQ   SEQUENCE   1581 AA;  168478 MW;  FCE0FE87EF08B887 CRC64;
     MKAQGETEES EKLSKMSSLL ERLHAKFNQN RPWSETIKLV RQVMEKRVVM SSGGHQHLVS
     CLETLQKALK VTSLPAMTDR LESIARQNGL GSHLSASGTE CYITSDMFYV EVQLDPAGQL
     CDVKVAHHGE NPVSCPELVQ QLREKNFDEF SKHLKGLVNL YNLPGDNKLK TKMYLALQSL
     EQDLSKMAIM YWKATNAGPL DKILHGSVGY LTPRSGGHLM NLKYYVSPSD LLDDKTASPI
     ILHENNVSRS LGMNASVTIE GTSAVYKLPI APLIMGSHPV DNKWTPSFSS ITSANSVDLP
     ACFFLKFPQP IPVSRAFVQK LQNCTGIPLF ETQPTYAPLY ELITQFELSK DPDPIPLNHN
     MRFYAALPGQ QHCYFLNKDA PLPDGRSLQG TLVSKITFQH PGRVPLILNL IRHQVAYNTL
     IGSCVKRTIL KEDSPGLLQF EVCPLSESRF SVSFQHPVND SLVCVVMDVQ DSTHVSCKLY
     KGLSDALICT DDFIAKVVQR CMSIPVTMRA IRRKAETIQA DTPALSLIAE TVEDMVKKNL
     PPASSPGYGM TTGNNPMSGT TTPTNTFPGG PITTLFNMSM SIKDRHESVG HGEDFSKVSQ
     NPILTSLLQI TGNGGSTIGS SPTPPHHTPP PVSSMAGNTK NHPMLMNLLK DNPAQDFSTL
     YGSSPLERQN SSSGSPRMEI CSGSNKTKKK KSSRLPPEKP KHQTEDDFQR ELFSMDVDSQ
     NPIFDVNMTA DTLDTPHITP APSQCSTPPT TYPQPVPHPQ PSIQRMVRLS SSDSIGPDVT
     DILSDIAEEA SKLPSTSDDC PAIGTPLRDS SSSGHSQSTL FDSDVFQTNN NENPYTDPAD
     LIADAAGSPS SDSPTNHFFH DGVDFNPDLL NSQSQSGFGE EYFDESSQSG DNDDFKGFAS
     QALNTLGVPM LGGDNGETKF KGNNQADTVD FSIISVAGKA LAPADLMEHH SGSQGPLLTT
     GDLGKEKTQK RVKEGNGTSN STLSGPGLDS KPGKRSRTPS NDGKSKDKPP KRKKADTEGK
     SPSHSSSNRP FTPPTSTGGS KSPGSAGRSQ TPPGVATPPI PKITIQIPKG TVMVGKPSSH
     SQYTSSGSVS SSGSKSHHSH SSSSSSSAST SGKMKSSKSE GSSSSKLSSS MYSSQGSSGS
     SQSKNSSQSG GKPGSSPITK HGLSSGSSST KMKPQGKPSS LMNPSLSKPN ISPSHSRPPG
     GSDKLASPMK PVPGTPPSSK AKSPISSGSG GSHMSGTSSS SGMKSSSGLG SSGSLSQKTP
     PSSNSCTASS SSFSSSGSSM SSSQNQHGSS KGKSPSRNKK PSLTAVIDKL KHGVVTSGPG
     GEDPLDGQMG VSTNSSSHPM SSKHNMSGGE FQGKREKSDK DKSKVSTSGS SVDSSKKTSE
     SKNVGSTGVA KIIISKHDGG SPSIKAKVTL QKPGESSGEG LRPQMASSKN YGSPLISGST
     PKHERGSPSH SKSPAYTPQN LDSESESGSS IAEKSYQNSP SSDDGIRPLP EYSTEKHKKH
     KKEKKKVKDK DRDRDRDKDR DKKKSHSIKP ESWSKSPISS DQSLSMTSNT ILSADRPSRL
     SPDFMIGEED DDLMDVALIG N
//
